CrushSCI.com
226.5Average days
189Median days
51Fastest days
565Longest days
4992025 publications

Paper Review Records

All Paper Review Records

21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

147 days

Advances in chimeric antigen receptor T (CAR-T) cell therapy and limitations for treating breast cancer requires next generation of CAR-T cells treatment

Authors
Yasir Nawaz; Hafiza Fizzah Riaz; Fouzia Tanvir; Basit NawazShow moreShow less
Affiliations
1. Department of Zoology, Faculty of Life Sciences, University of Okara, Okara, Pakistan; 2. Department of Zoology, The Islamia University of Bahawalpur, Rahim Yar Khan Campus, Pakistan; 3. Department of Chemistry, University of Agriculture Faisalabad, Faisalabad, PakistanShow moreShow less
Source PDF DOI Publisher page
541 days

Mesenchymal phenotype drives high metabolic tumor volume in pancreatic cancer: integrated transcriptomic and single-cell analysis of tumor-stroma metabolic interactions

Authors
Nan Zhou; Jiahui Yuan; Dajun Du; Xiuqing Wang; Tiantian Yang; Zhijun FengShow moreShow less
Affiliations
1. Department of Medical Oncology, Xinyang Key Laboratory of Oncology, Xinyang Central Hospital, Xinyang Normal University Affiliated Hospital, Xinyang City, China; 2. Department of General Surgery, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Shenzhen University General Hospital, Shenzhen University, Shenzhen, China; 3. Department of Surgical Oncology, Xinyang Central Hospital, Xinyang Normal University Affiliated Hospital, Xinyang City, China; 4. Clinical Research Unit, The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
565 days

The multifaceted role of a-to-i rna editing in tumorigenesis: from coding to noncoding RNAs

Authors
Hussein Sabit; Rawan M. Abdelazeem; Aysha Ghazy; Nouran Mohamed; Shaimaa Abdel-GhanyShow moreShow less
Affiliations
1. Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza, Egypt; 2. Department of Agriculture Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza, Egypt; 3. Department of Environmental Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza, EgyptShow moreShow less
Source PDF DOI Publisher page
219 days

Metabolic targeting of multiple myeloma using the Warburg Trap

Authors
Nina Hildenbrand; Elena Tripel; Svitlana Melnik; Daniel Strelzov; Alexandra M. Poos; Lukas John; Niels Weinhold; Marc A. Baertsch; Tilman Walker; Burkhard Lehner; Jörg FellenbergShow moreShow less
Affiliations
1. Research Centre for Molecular and Regenerative Orthopaedics, Department of Orthopaedics, Heidelberg University Hospital, Heidelberg, Germany; 2. Department of Orthopaedics, Medical Faculty, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany; 3. Department of Orthopaedics, Heidelberg University Hospital, Heidelberg, Germany; 4. Heidelberg Myeloma Center, Department of Internal Medicine V, Medical Faculty, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany; 5. Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University, German Cancer Research Center (DKFZ), Heidelberg, GermanyShow moreShow less
Source PDF DOI Publisher page
107 days

Refined on-tissue chemical derivatization expands MALDI-MSI capabilities for spatial metabolomics of mammalian organs and metastatic tumors using EDC and 4-APEBA

Authors
Antonia Fecke; Luiza Martins Nascentes Melo; Ann-Cathrin Groba; Gabriele Allies; Feyza Cansiz; Siva Swapna Kasarla; Sven Heiles; Albert Sickmann; Alpaslan Tasdogan; Karl W. SmithShow moreShow less
Affiliations
1. Leibniz-Institut für Analytische Wissenschaften—ISAS—e.V, Dortmund, Germany; 2. Department for Dermatology, Venerology and Allergology, Research Center One Health, University Hospital Essen, German Cancer Consortium, Partner Site Essen & University Alliance Ruhr, Essen, Germany; 3. Lipidomics, Faculty of Chemistry, University of Duisburg-Essen, Essen, Germany; 4. Medizinische Fakultät, Medizinische Proteom-Center (MPC), Ruhr-Universität Bochum, Bochum, GermanyShow moreShow less
Source PDF DOI Publisher page
394 days

The dual tumor-suppressive mechanisms of STAM in clear cell renal cell carcinoma: EGFR inactivation and autophagy activation via AKT regulation

Authors
Zugen Chen; Leqi Liang; Lei Peng; Menghua Liao; Wenxia Lv; Shan Ao; Zikun Peng; Ming Lei; Di Gu; Yongda Liu; Guohua Zeng; Tuo DengShow moreShow less
Affiliations
1. Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; 2. Guangdong Provincial Key Laboratory of Urological Diseases, Guangzhou Medical University, Guangzhou, China; 3. Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Medical University, Guangzhou, China; 4. Guangzhou Institute of Urology, Guangzhou Medical University, Guangzhou, China; 5. Guangzhou, ChinaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Cancer Cell International take to review a manuscript?

As of 2026-11-18, CrushSCI has 21 complete review records for Cancer Cell International. The fastest paper went from submission to acceptance in 51 days (Mixed phenotype acute leukemia across lineage boundaries: from classification to clonal biology and precision therapy, received 2026-08-23, accepted 2026-10-13); the slowest took 565 days. The average is 226.5 days and the median is 189 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.